In CNS Pharma clinical trials, clearing subjects and establishing baselines may improve the interpretation of results and reduce confounding data by enriching the subject pool for the prospective trial. Qualitative EEG (qEEG) can be used in various ways to achieve subject enrichment.  This webinar covers the strengths and limitations of EEG and qEEG approaches in clinical trials and discusses the importance of standardization in EEG reading and qEEG interpretation.

Application has been made with ASET for 1 CEC for this event.

Co-Presenters - Dr. Dona Murphey and Dr. Brandon Westover
​​​​​​​
M. Brandon Westover, MD, PhD obtained his PhD in Physics working in information theory and computer vision. He is a board-certified practicing Neurologist and Clinical Neurophysiologist at Massachusetts General Hospital (MGH), where he directs the MGH Critical Care EEG Monitoring Service and MGH Clinical Data Animation Center (CDAC), and serves as the Director of Data Science at the McCance Center for Brain Health. His group develops machine learning / AI approaches to improve medical care for patients with neurological conditions including anoxic brain injury, seizures, cerebral ischemia, delirium, and sleep disorders. He co-founded Beacon Biosignals.
 
Dr. Murphey completed her M.D. / Ph.D. and fellowship in clinical neurophysiology (EEG / epilepsy) at Baylor College of Medicine and undergraduate degree at Harvard. She served as Medical and Scientific Director at CortiCare for three years and continues to support the commercialization of diagnostic algorithms and the growth of our clinical trials unit.